(1S,2S,13R)-22-(cyclopropylmethyl)-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (1S,2S,13R)-22-(cyclopropylmethyl)-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
• 化学式: C₂₆H₂₆N₂O₃
• 分子量: 414.5
• InChiKey: WIYUZYBFCWCCQJ-OOGIKFLQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  2
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  68.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Octahydroisoquinoline compounds as opioid receptor modulators
  申请人：Carroll Ivy Frank

  公开号：US20070027182A1

  公开（公告）日：2007-02-01

  Compounds which bind to opioid receptors are provided. In a preferred embodiment of the invention, the compounds are opioid receptor antagonists. The present invention also provides methods of treating conditions which are mediated by an opioid receptor.

  提供结合到阿片受体的化合物。在发明的首选实施例中，这些化合物是阿片受体拮抗剂。本发明还提供了治疗由阿片受体介导的疾病的方法。
• QUATERNARY OPIOID CARBOXAMIDES
  申请人：Wentland Mark P.

  公开号：US20120302594A1

  公开（公告）日：2012-11-29

  Compounds of formulas: are disclosed. The compounds are useful for ameliorating the side effects of therapeutic opiates.

  公式为的化合物被披露。这些化合物可用于改善治疗阿片类药物的副作用。
• Molecular adjuvants for enhanced cytosolic delivery of active agents
  申请人：Universiteit Gent

  公开号：US11033572B2

  公开（公告）日：2021-06-15

  The present invention relates to a method and compositions for optimized intracellular delivery of active agents, in particular nucleic acids, using a specific class of adjuvants. The method and compositions of the invention enhance cytosolic release of the agents and can be used for the treatment of various disorders.

  本发明涉及一种使用特定类别佐剂优化活性剂（尤其是核酸）细胞内递送的方法和组合物。本发明的方法和组合物能增强药剂的细胞释放，可用于治疗各种疾病。
• 8-CARBOXAMIDO-SUBSTITUTED-2 , 6-METHANO-3-BENZAZOCINES AND 3 - CARBOXAMIDO- SUBSTITUTED MORPHANES AS OPIOID RECEPTOR BINDING AGENTS
  申请人：RENSSELAER POLYTECHNIC INSTITUTE

  公开号：EP1924559B1

  公开（公告）日：2014-04-16
• Opiate analogs selective for the delta-opioid receptor
  申请人：Welsh J. William

  公开号：US20070105884A1

  公开（公告）日：2007-05-10

  Novel compounds which selectively bind to the δ-opioid receptor have been designed. These compounds have greater selectivity, improved water (blood) solubility, and enhanced therapeutic value as analgesics. Because agonists with selectivity for the δ-opioid receptor have shown promise in providing enhanced analgesis without the addictive properties, the compounds of the present invention are better than morphine, naltrindole (NTI), spiroindanyloxymorphone (SIOM), and other known μ-opioid receptor selectors as analgesics.